Mlp Saglik Hizmetleri As Class B · BIST:MPARK
Mlp Saglik Hizmetleri As Class B — MLP Care — H1 2021 Earnings Presentation
23 slides from Mlp Saglik Hizmetleri As Class B's earnings presentation, Aug 13, 2021
Slide 1: MLP Care H1 2021 Presentation
MLP CARE H1 2021 PRESENTATION AUGUST 13, 2021
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation may contain certain forward-looking statements concerning MLP Care’s future performance and should be considered as good faith estimates made by the Company. These forward-looking statements reflect management expectations and are based upon currently ava
Slide 3: Muharrem Usta, Chairman & CEO
MUHARREM USTA CHAIRMAN & CEO MLPCARE MEDICALPARK | Lit/nosprtaL
Slide 4: At a Glance: MLP Care Q2 2021 Financial Highlights
At a Glance: MLP Care Q2 2021 Financial Highlights (w/o fx impact) Adj. EBITDA Revenue Low base of last year supported both domestic and foreign medical revenue TL 1,331 m TL 320 m 75% Growth 63% Growth growth H1 2021: H1 2021: 46% Growth 53% Growth Net profit improved mainly due to strong ope
Slide 5: # of People with Top-up Insurance Over 2 million
# of People with Top-up Insurance Over 2 million # of People with Insurance in Turkey (in thousand) 2,399 2,022 4,421 2,282 1,501 3,784 Growth (H1 2020 – H1 2021) 5.1% 34.7% 16.8% PMI Top-up PMI+Top-up # of People with Top-up Insurance in Turkey (in thousand) 06.2021; 2,022 06.2020; 1,501 Average LT
Slide 6: At a Glance: MLP Care Operational Highlights
At a Glance: MLP Care Operational Highlights Two brands and one concept targeting three different price points with The largest hospital group in 30 Hospitals in consistently outstanding medical service Total Turkey quality Established in 1993, listed on BIST in 2018 ~18,000 Staff 1 ~6,000 Beds in T
Slide 7: Liv Hospital Brand Expands in İstanbul
Liv Hospital Brand Expands in İstanbul Map of Istanbul Liv Hospital VadIstanbul Hospitals with Medical Park Brand Location: Sarıyer / Istanbul Hospitals with Liv Hospital Brand Opening Date: May 2021 Key Statistics 37k sqm 125 bed capacity 76 policlinic rooms 7 operating rooms MLP Care hos
Slide 8: Burcu Öztürk, CFO
BURCU OZTURK CFO MLPCARE MEDICALPARK | Lit/nosprtaL
Slide 9: Strong Revenue Growth Supported by Low Base
Strong Revenue Growth Supported by Low Base Revenue (TLm) 46.3% 2,542 75.3% 1,738 1,331 759 Q2 2020 Q2 2021 H1 2020 H1 2021 Denotes growth of Revenue vs. the same period of the last year 9
Slide 10: Strong Revenue Growth Supported by Low Base
Strong Revenue Growth Supported by Low Base H1 2021 (48%) 87% Revenue from SSI was up by 26% in Q2 2021 3% (SSI Insurance allows for a wide addressable market, 10% which is c.98% of the total population) 29% 26% Self pay was up by 71% in Q2 2021 Revenue from PMI, Top-up & Contracted Institutio
Slide 11: Strong Revenue Growth Supported by Low Base
Strong Revenue Growth Supported by Low Base Domestic Patient Medical Tourism Ancillary Business Revenue Revenue 50.5% 87.1% (48.5%) 72.2% 308.5% 2,225 (42.7%) 253 64 1,157 144 30 Q2 2021 H1 2021 Q2 2021 H1 2021 Q2 2021 H1 2021 Domestic Revenue q-o-q Growth Accelerated Recovery of Decrease in Laborat
Slide 12: Continued Improvement in Average Prices
Such unit price improvements create a sustainable Continued Improvement in Average Prices Outpatient Revenues (TLm) Inpatient Revenues (TLm) 62.3% 43.4% 42.2% 34.4% 20.1% 9.1% 318 234 111 898 1,327 84 553 926 H1 2020 Volume & Mix Price H1 2021 H1 2020 Volume & Mix Price H1 2021 Average Revenue Per V
Slide 13: EBITDA Growth on the Back of Strong Revenue Recovery
EBITDA Growth on the Back of Strong Revenue Recovery EBITDA (TLm) EBITDA2 (TLm) (w/o fx impact) 48.8% 52.7% 676 633 50.6% 454 62.8% 414 330 320 219 196 Q2 2020 1 Q2 2021 1 H1 2020 1 H1 2021 1 Q2 2020 2 Q2 2021 2 H1 2020 2 H1 2021 2 1 Adj. EBITDA: EBITDA TFRS adjustments that have no cash impact on r
Slide 14: Prudent Cost Management
Prudent Cost Management Cost of Service and G&A Expenses as a % of Revenues Cost Saving Measures enables us to reach the favourable EBITDA Margin Adj. EBITDA Margin 26.1% 26.6% Material costs as a % of revenue declined in H1 2021 1.0% 0.8% due to decrease in the share of laboratory business which
Slide 15: Strong Net Profit Improvement
Strong Net Profit Improvement Net Profit (TLm) Net Profit (TLm) Allocated to Equity Holders of the Parent 344.5% 435.8% 174 147 95 82 (22) 39 (23) 27 Q2 2020 Q2 2021 H1 2020 H1 2021 Q2 2020 Q2 2021 H1 2020 H1 2021 Denotes growth of Net Profit and Net Profit Allocated to Equity Holders of the Parent
Slide 16: FX Exposure in Net Debt Eliminated in February 2021
FX Exposure in Net Debt Eliminated in February 2021 FX BASED NET DEBT 1 (in EUR m) GROSS DEBT PERCENTAGE 2020 H1 2021 EUR30m EUR32m EUR27m equivalent of equivalent of equivalent of Cash Balance 580mTL Cash Balance 375mTL FX Cash FX Cash FX Cash Balance Balance Balance 15% 21% 85% 79% 65 51 Net Debt
Slide 17: Improved Free Cash Flow and Operating Cash Flow
Improved Free Cash Flow and Operating Cash Flow Maintenance Capex (TLm) Total Capex (TLm) OCF/ EBITDA FCF/ EBITDA 101.4% 76.4% 2.1% 6.7% 1.9% 78.9% 685 66.4% 3.3% 169 516 53 359 33 302 57 H1 2020 H1 2021 H1 2020 H1 2021 H1 2020 H1 2021 H1 2020 H1 2021 % of Revenue % of Revenue % of EBITDA % of EBITD
Slide 18: Q&A
Q&A MLPCARE MEDICALPARK | Lit/nosprtaL
Slide 19: Closing Remarks
Closing Remarks MUHARREM USTA CHAIRMAN & CEO
Slide 20: Thank You!
Thank You! MLP Care Investor Relations Deniz Can Yücel +90 212 227 5555 (Ext: 1148) deniz.yucel@mlpcare.com http://investor.mlpcare.com/en/
Slide 21: Historical Balance Sheet
Historical Balance Sheet Reviewed Reviewed Audited TLm June 30, 2021 June 30, 2020 December 31, 2020 Cash and cash equivalents 580 470 375 Trade receivables 1,279 1,080 1,155 Inventory 118 107 113 Short term other assets 454 392 542 Current assets 2,431 2,049 2,185 Tangible and intangible fixed asse
Slide 22: Historical P&L Statements
Historical P&L Statements H1 2021 H1 2020 Change (%) Q2 2021 Q2 2020 Change (%) TLm Revenue 2,542 1,738 46.3% 1,331 759 75.3% Cost of service (-) (1,907) (1,351) 41.2% (999) (601) 66.3% Gross profit 635 388 63.9% 332 159 109.3% General administration expenses (-) (194) (113) 71.8% (109) (39) 181.0%
Slide 23: Reconciliation from Reported EBITDA to Adjusted EBITDA
Reconciliation from Reported EBITDA to Adjusted EBITDA TLm H1 2021 H1 2020 Q2 2021 Q2 2020 Net profit / (loss) 174 39 95 (22) Tax (income) from operations 14 25 (21) (0) Depreciation and amortization of tangible and intangible fixed assets 154 125 81 63 Total interest expenses/(income) and fair valu